Asthma | 10 | UK (9), Australia (1) | Annual review40 42–44 | 4 | 100% | Range: 32–82% | British Thoracic Society Guidelines 1993; The National Asthma Campaign Asthma Management Plan 1996 |
| | | | | | Median: 63%; Mean: 60% | |
| | | Smoking status recorded40 42 | 2 | 100% | 19% and 80% | |
| | | PEFR recorded40 44 | 2 | 100% | 36% and 77% | |
| | | Appropriate use of prophylactic treatment45–47 | 3 | 100% in those patients with at least moderate asthma | Range: 11–73% | |
| | | | | | Median 25%; Mean 36% | |
| | | Management of acute attacks48 49 | 2 | Nebulised bronchodilators. | 32% and 35% | |
| | | | | Systemic steroids | 71% and 72% | |
Cardiovascular disease | 17 | UK | Prescribing: | 13 | | | |
| | | Aspirin17 18 50–59 | 12 | 100% (if no contraindication) | Range: 49–92% | East London Clinical Guidelines Project 1995 Trials: ISIS-2 1988; Antiplatelets Trialists' Collaboration 1994; Beta-blocker Heart Attack Trial Research Group 1982; Norwegian Multicenter Study Group 1981; SAVE 1992; SOLVD 1991; 4S Study 1994 |
| | | | | | Median: 71%; Mean: 72% | |
| | | Beta-blockers18 51 57 | 3 | 100% with recent AMI, no contraindications | Range: 27–47% | |
| | | | | | Median: 32%; Mean: 35% | |
| | | ACE inhibitors18 25 50 57 60 | 5 | 100% with history of heart failure, no contraindications. | Range: 40–65% | |
| | | | | | Median: 48%; Mean: 50% | |
| | | Lipid lowering agents19 50 51 53 | 4 | Differing levels of TC requiring treatment (≥5.5 or ≥6.5 mmol/l) | Range: 11–59% | |
| | | | | | Median: 19%; Mean: 27% | |
Diabetes | 11 | UK (7), NZ (2), Australia (2) | Glycaemic control: | | | | RCGP guidelines 1993; British Diabetic Association Guidelines 1993; RACGP Diabetes Guidelines |
| | | HbA1c/ fructosamine recorded40 61–69 | 9 | 100% | Range: 25–100% | |
| | | | | | Median: 76%; Mean: 71% | |
| | | HbA1c controlled: | | 100% | | |
| | | <6 SD above normal population mean61 | 1 | | 45% (IDDM), | |
| | | <4 SD above normal population mean63 68 | 2 | | 75% (NIDDM) | |
| | | <9.1%67 | 1 | | 46% and 63% | |
| | | <7.5%69 | 1 | | 82% | |
| | | | | | 27% | |
| | | Recording of risk factors: | | 100% | | |
| | | BP40 62–66 69 | 7 | | 69–93% | |
| | | Wt/BMI40 62 63 65 66 69 | 6 | | 40–85% | |
| | | Smoking40 62 63 | 3 | | 35–68% | |
| | | Lipids/cholesterol62–66 69 | 6 | | 25–83% | |
| | | Renal function62–64 | 3 | | 45–82% | |
| | | Screening: | | 100% | | |
| | | Eye examination: | | | | |
| | | In previous 12 months40 65 69 | 3 | | 21–37% | |
| | | In previous 24 months 63 64 66 67 70 | 5 | | 44–72% | |
| | | Foot examination: | | | | |
| | | In previous 12 months40 65 66 69 | 4 | | 3–49% | |
| | | In previous 24 months63 64 | 2 | | 29% and 66% | |
| | | Urinalysis | | | | |
| | | In previous 12 months65 66 | 2 | | 0.3% and 42% | |
| | | In previous 24 months64 | 1 | | 39% | |
Hypertension | 11 | UK (10), Australia (1) | Percentage of patients ≥65 years with blood pressure recorded21–23 | 3 | 100% | 77–86% | British Hypertension Standards; New Zealand Guideline; WHO guideline; US guideline; Canadian guideline. |
| | | Percentage who had 3 BP recordings taken before initiation of treatment71 23 | 2 | 100% | 79% and 87% | |
| | | Percentage of those with hypertension receiving treatment21 22 72 | 11 | 100% | 51–64% | |
| | | Percentage with controlled blood pressure | | | 20% (US) to 90% (Canada) | |
| | | All guidelines73 74 | 2 | 100% | 31–83% | |
| | | British Hypertension Standards21 22 24 41 71–76 | 9 | | | |
| | | Percentage with sitting and standing BP recorded22 | 1 | 100% | 3% | |